Sonic Incytes Medical Announces Multi-Year Partnership With Madrigal Pharma To Advance Assessment And Risk Stratification Of Patients With Or At Risk For MASH
Benzinga Newsdesk 4 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.Sonic Incytes Medical Corp.,
Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.
Sonic Incytes Medical Corp., developer of the Velacur™ point-of-care liver assessment platform, today announced a multi-year partnership with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for MASH, to advance the assessment and risk stratification of patients with or at risk for MASH.
